Desidustat Tablet is being studied for the management of Covid-19. Credit: Masum Ali from Pixabay.

India-based pharmaceutical company Zydus has received approval from the Mexican regulatory authority, COFEPRIS, to assess Desidustat as a potential Covid-19 treatment.

Mexico-based contract research organisation (CRO) Avant Santé Research Center will be responsible for the clinical and regulatory development of the drug in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Zydus will perform a multi-centre, open-label, randomised, comparator-controlled Phase IIb trial to assess the safety and efficacy of Desidustat Tablet for the management of the disease.

During the study, 100mg tablets of the drug will be given for 14 days, along with recommended standard care.

Zydus Cadila chairman Pankaj Patel said: “At Zydus, we have been stepping up our efforts to fight the Covid-19 pandemic through therapeutic drugs, diagnostics and vaccines. With Desidustat, we will study a novel approach for the management of Covid-19.”

Patients with Covid-19 are known to experience signs of ‘hypoxia’, which can cause organ failure and death, even after the use of antivirals, anti-inflammatory drugs, or ventilators.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The disease is said to decrease the amount of haemoglobin that can carry oxygen and carbon dioxide, leading to intense poisoning and inflammation in lung cells.

Desidustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

At higher altitudes, the body responds to lower availability of oxygen by stabilising hypoxia-inducible factor, causing increased red blood cell production and improved oxygen delivery to tissues.

The drug is currently being studied in Phase III trials for treating chronic kidney disease patients.

Last week, Zydus secured regulatory approval from the Drug Controller General of India (DCGI) to conduct Phase I/II human trials of its Covid-19 vaccine candidate, named ZyCoV-D.